Survival has improved among patients with diffuse large B-cell lymphoma (DLBCL) with the addition of anti-CD20 antibody therapy. We aimed to quantify trends and remaining loss in expectation of life (LEL) due to DLBCL at a national population-based level. Patients diagnosed with DLBCL 2000-2013 (N 5 7114) were identified through the Swedish Lymphoma Registry and classified according to the age-adjusted International Prognostic Index (aaIPI). The novel measure LEL is the difference between remaining life years among patients and the general population and was predicted using flexible parametric models from diagnosis and among 2-year survivors, by age and sex. Median age at DLBCL-diagnosis was 70 (18-105) years and 54.8% presented with stage III-IV disease. On average, LEL due to DLBCL decreased from 8.0 (95% CI: 7.7-8.3) to 4.6 (95% CI: 4.5-4.6) years over the study period. By risk group, LEL was most reduced among patients with aaIPI 2 aged 50-60 years. However, these patients were still estimated to lose >8 years in 2013 (eg, LEL males50years 8.6 years (95% CI: 5.0-12.3)). Among 2-year survivors, LEL was reduced from 6.1 years (95% CI: 5.6-6.5) (aaIPI 2) and 3.8 years (95% CI: 3.6-4.1) (aaIPI < 2) to 1.1 (95% CI:
| I N T R O D U C T I O N
Prognosis in diffuse large B-cell lymphoma (DLBCL) has improved following the addition of anti-CD20 antibody treatment to standard chemotherapy (rituximab plus cyclophosphamide, doxorubicine, vincristine, and prednisone (R-CHOP)). [1] [2] [3] [4] [5] However, about one-third of the patients still experience treatment-refractory disease or relapse and consequently a dramatic worsening of the prognosis. 1, 6 Recent studies have highlighted the importance of obtaining complete remission on first-line therapy to achieve cure. 6, 7 Maurer et al showed that patients in the US and France who reached event-free survival at 24 months (EFS24) had similar survival as DLBCL-free individuals in the general population. Jakobsen et al. identified post-treatment EFS24 (pEFS24)
as decisive for a favorable outcome among Danish DLBCL patients in first complete remission, although survival did not normalize to that of Preliminary results of this study were presented as an oral presentation at 14-ICML in Lugano June 16, 2017. the general population among patients 50 years. 7 Apart from presenting alternative surrogate endpoints of favorable outcomes for future use in clinical trials, these studies also highlight the clinical value of contrasting DLBCL patient survival with survival in the general population.
Loss in expectation of life (LEL) quantifies the number of life-years lost due to cancer by incorporating life expectancy in matched individuals from the general population. 8, 9 Because the LEL accumulates across the entire life span, it provides an easy-to-interpret and clinically relevant measure of the impact of cancer on affected individuals.
Here we have investigated trends in life-years lost due to DLBCL in clinical subgroups of patients from the pre-to the post-rituximab era (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) to identify and illustrate remaining unmet medical needs at the population level.
| M E T H O D S

| Study population and setting
The Swedish health care system is tax funded and offers universal access to specialized care in hematology/oncology to all residents. The final study cohort encompassed 7114 individuals with de novo DLBCL. Data was linked to the cause-of-death register for follow-up, holding dates and causes of death with >99% coverage, via the unique national registration number assigned to all Swedish residents. 14 Data was also linked to the national patient register to identify diagnoses of HIV/AIDS prior to DLBCL. The study was approved by the regional ethical review board in Stockholm.
| Risk groups and treatment practices
The patients were classified into risk groups based on the age-adjusted
International Prognostic Index (aaIPI) 15 
| Statistical methods
Loss in expectation of life is defined as the difference between the life expectancy the patients would have had in the absence of DLBCL, and the life expectancy that patients face in the presence of DLBCL. The former is typically obtained via publicly available life tables for the entire general population whereas the life expectancy in the patients is estimated by extrapolating the all-cause survival function for the patients. 16 We used flexible parametric survival models adapted for relative survival to estimate LEL. 17, 18 This model is similar to Cox regression but uses restricted cubic splines to explicitly model the excess cumulative baseline hazard function. Two models where fitted including calendar-year and age at diagnosis (both using restricted cubic splines) and sex (model 1) and risk group (aaIPI < 2/aaIPI 2) (model 2). To account for non-proportional hazards, time-dependent effects for all covariates except sex were estimated by including interaction terms between the variables in question and the spline terms representing the baseline cumulative excess hazard. Estimates of the expected survival were retrieved from the Human Mortality Database project and matched to the patients based on age, sex and calendar-year. 19 All patients were followed from date of diagnosis until death, or December 31st 2014, whichever occurred first.
We also quantified the proportion of expected life lost (PELL);
obtained by dividing the number of life-years lost by the life-expectancy in the population. This measure is useful for comparing groups where the difference in life expectancy in the absence of cancer is large.
Conditional LEL and PELL were estimated for patients surviving the first 2 years after diagnosis (OS24) by dividing the model-based survival estimates after 2 years of follow-up by the survival estimates at 2 years. The conditional analysis was restricted to patients diagnosed 2000-2012 since patients diagnosed in 2013 could not be followed for 2 years.
|
The probabilities of dying from lymphoma (underlying cause of death: ICD10: C82, C83, C85, C88, C91.1, C81.9, C96.9) in the presence of competing risks; cardiovascular diseases (ICD10: I00-I99), malignancy other than lymphoma (ICD10: C00-C99, D00-D99), or other causes were also predicted from flexible parametric survival models adjusted for riskgroup (aaIPI < 2,age < 70/aaIPI < 2,age 70/ aaIPI 2, age < 70/aaIPI 2, age 70). For a more detailed specification of the regression models used, see the statistical appendix.
| R E S U LTS
Of 7114 patients diagnosed with de novo DLBCL, 54.9% were males ( Table 2 ). During the study period, for men diagnosed at age 50, LEL decreased from 11.9 years (95% CI: 10.0-13.7) to 5.6 years (95% CI: 3.3-7.8) and for 70-year-old men from 7.6 (95% CI:
6.9-8.3) to 4.8 years (95% CI: 3.6-6.1). The corresponding LEL for women decreased from 12.5 (95% CI: 10.5-14.6) to 5.7 years (95% CI:
3.2-8.1) and from 9.0 (95% CI: 8.1-9.9) to 4.8 years (95% CI: 3.6-6.1) (Figure 1 , Supporting Information Table 2 ). The PELL, also decreased during the study period. Although young patients lost more years in absolute terms, the PELL was greater for elderly patients (Supporting Information Figure1 and Table 2 ). Deaths due to other causes than lymphoma were primarily observed in patients >70 years at diagnosis. For patients who reached OS24, the 5-year probability of lymphoma-related death was substantially lower for all ages and risk groups (Supporting Information Figure3).
For example, the 5-year probability of death due to lymphoma among high-risk patients diagnosed at age >70 in 2007-2013 was 59.3% (95% CI: 56.0-62.6). When conditioning on OS24, the 5-year probability of lymphoma-related death was 13.3% (95% CI: 9.1-17.5). Among low-risk patients diagnosed at >70 years, lymphoma was no longer the dominant cause of death when conditioning on OS24 (Supporting Information Table 4 ).
| D IS C U S S I O N
Using a novel measure, we illustrate and quantify recent improvements experienced late relapses within the subsequent 5 years. 6 The results
were replicated in a French multicenter cohort of similar size. A population-based study originating from the Danish Lymphoma Register, by Jakobsen et al., 7 showed that among 1621 patients in complete remission after first-line therapy with R-CHOP (or equivalent), and who achieved 24 months of post-treatment event-free survival, pEFS24, survival was only slightly reduced compared to the general population.
When stratifying on age, patients younger than 50 years at diagnosis experienced a survival comparable to the general Danish population.
In our study, using a truly population-based perspective without restrictions based on treatment intent or response, patients diagnosed in 2012 who reached OS24 had a life expectancy that was within a few years from that of the general population, irrespective of age at diagnosis and risk-group. For patients younger than 50 years at diagnosis there was no statistically significant LEL from OS24 suggesting that patients no longer experience excess mortality due to DLBCL. Hence, it appears that OS24 approaches the value of EFS24 as an alternative outcome measure. Still, both measures need to be further validated against primary long-term endpoints. Since the reporting of relapse to the Swedish Lymphoma register only began toward the end of the study period, EFS could not be investigated in this study.
From a clinical point of view, it is important to report results conditioned on duration of follow-up as prognosis changes substantially after the first critical time of diagnosis and treatment. This is the first study to evaluate time trends in conditional survival reflecting the transition into the rituximab era, and to show a marked improvement at this time point. The change likely indicates a lower risk of late relapses which has been noted by others. Maurer et al found that 70% of all relapses occurred within the first year after diagnosis. 6 In our competing risk analysis, we found that high-risk patients aged >70 at diagnosis 2007-2013 had a 60% risk of dying from lymphoma within 5 years.
For patients who reached OS24, the corresponding 5-year risk of dying of lymphoma was 13%. These analyses were based on data from the cause-of-death register. This register was validated in 2000 and had an agreement of 90%-98% for severe conditions. 20 To our knowledge, loss in expectation of life considering the entire life span has not been used previously in studies of DLBCL. In the Danish study by Jacobsen et al., another life expectancy measure was utilized with a restricted mean survival approach where the estimation of LEL was limited to the first ten years after diagnosis. To fully capture the impact of treatment regimens and patient management on survival, we favor estimation of LEL over the entire life span, as opposed to the restricted version, since this measure is much easier to interpret.
Estimating LEL requires extrapolation of survival beyond available data.
To this end we used novel statistical methodology developed by
Andersson et al. which has been shown to accurately predict long-term cancer patient survival via a relative survival approach to extrapolation. 21 Notwithstanding this, the extrapolated rates should be interpreted with care, especially in young patients, as the models assume that no unpredictable changes in the trends of the mortality occur.
Another, potential limitation of this and other studies 6, 7 is the short follow-up for the most recently diagnosed patients which prevents capture of fatal late effects due to the treatment.
A strength of the current study is the population-based cohort identified in the SLR which allowed comparisons by clinical risk groups.
Ziepert et al. has shown that aaIPI remains a valid prognostic tool in the rituximab era. 22 A limitation is that the register did not allow for More intensive treatment at older ages and improved supportive care at both primary and second-line settings are also likely to contribute.
In conclusion, we provide a novel tool to illustrate recent gains and remaining unmet needs in DLBCL using loss in expectation of life.
Despite improvements following the introduction of rituximab, the results highlight continued large losses of life among young high-risk patients with primary refractory disease and early relapse as the most important challenges of current DLBCL practice. 
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